SignalChem Life Sciences Corp
SignalChem is a clinical stage company that has developed one of the most robust functional protein libraries which allows for the development of highly selective proprietary compounds. These chemical entities can be used to fulfill personalized medicine strategies. The company is seeking a partner for its AXL therapeutic development program (expected to enter into Phase 1 in early 2019), and also seeking new development partnerships.
Conference Objective
Demonstrate how company’s functional protein platform and chemistry expertise can accelerate drug development efforts
Partnering Objective
Identify a clinical development partner for SLC-391, which targets AXL tyrosine kinase. AXL is a member of the TAM family of kinases and plays a critical role in resistance and more recently has been demonstrated to play a key role in immune tolerance. Immune tolerance is key in evasion of the immune system, and breaking this tolerance is of paramount importance as part of immune-oncology. The company is seeking a partner for its AXL therapeutic development program (expected to enter into Phase 1 in early 2019), and also seeking new development partnerships.
Delegate Contacts
Anthony is an advisor to SLC, and assists the company with BD and clinical activities. He has taken IVD products from discovery to the clinic with a strong aptitude for business as a serial entrepreneur across different business segments
Jun is the president of SignalChem and has extensive experience in protein engineering and drug discovery. Jun also has an acumen for business as a serial entrepreneur.